Stanford scientists have discovered a novel approach to address cardiovascular complications resulting from cancer chemotherapy, particularly those caused by tyrosine kinase inhibitors (TKIs).
Stanford researchers have developed an innovative, non-invasive therapeutic strategy to treat myocardial fibrosis (MF), a key driver of arrhythmia and heart failure in LMNA-related dilated cardiomyopathy (LMNA-DCM).